股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣東東陽光藥業股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06887 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 112,712,832 RMB | | | 1 RMB | | 112,712,832 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 112,712,832 RMB | | | 1 RMB | | 112,712,832 | 備註： 第 1 頁 共 11 頁 v 1.1.1 FF3 ...

Group 1 - The Hang Seng Index fell by 0.4%, while the Hang Seng Tech Index decreased by 0.54%, with a total turnover of 152 billion HKD in the Hong Kong stock market during the morning session [1] - The Hang Seng Biotechnology Index rose by 1%, with notable gains from companies such as MicroPort Scientific Corporation (02252) up by 10%, and Four Seasons Medicine (00460) up by 8% [1] Group 2 - MicroPort Scientific Corporation (02252) saw a rise of over 10%, indicating renewed interest in the robotics industry and steady progress in the company's commercialization efforts [2] - Dongyang Sunshine Pharmaceutical (06887) increased by nearly 7%, reporting a mid-term gross profit of 1.468 billion HKD, with key data on Ifenprodil presented at the US IPF summit [2] - Chuangsheng Group-B (06628) surged over 28%, with a mid-term net loss narrowing by 17.9%, and TST001 research data making its debut at ASCO [2] - Kingsoft Holdings (03918) rose by over 6%, with first-half performance exceeding market expectations, although uncertainties remain regarding the Naga3 project according to Citigroup [2] - Green Power Environmental (01330) increased by over 7%, with a 24.49% year-on-year increase in net profit attributable to shareholders, driven by its gas supply business [2] - Hylink Technology (01860) rose by 7.9%, with first-half revenue increasing by 40% year-on-year, and institutions optimistic about the continued release of the Mintegral platform's flywheel effect [2] - Zhi Zi Cheng Technology (09911) rose by over 6%, with first-half net profit nearly doubling, and the group's gross profit margin expected to improve significantly year-on-year [2] - Four Seasons Medicine (00460) rose by over 7%, achieving profitability in the first half and making substantial progress in its AI + medical beauty strategic layout [2] - Guofu Quantum (00290) increased by 6.86%, with a cumulative increase of nearly 1.8 times this year, collaborating with Huajian Medical to advance RWA ecosystem construction [2] - New Idea Network Group (01686) fell by over 17% post-results, with annual net profit increasing by 8% to 979 million HKD [2]

Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) reported a revenue of 1.938 billion RMB for the first half of 2025, with a gross profit of 1.468 billion RMB, indicating a significant impact from the reduced flu epidemic compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 1.938 billion RMB and a gross profit of 1.468 billion RMB for the first half of 2025 [1] - The sales revenue from the oseltamivir product, a preferred flu medication, was 1.301 billion RMB, reflecting a decline due to the flu epidemic's slowdown [1] Group 2: Product Development and Innovation - Dongyang Sunshine Pharmaceutical showcased its innovative anti-fibrotic drug, HEC585, at the 9th Idiopathic Pulmonary Fibrosis (IPF) Summit held in Boston from August 19 to 21, 2025 [1] - HEC585 is the first domestically developed IPF new drug to enter Phase III clinical trials and has potential applications for progressive fibrosing interstitial lung disease (PF-ILD), hepatitis B liver fibrosis, and interstitial pneumonia [2] - The drug works by simultaneously inhibiting the release of TNF-α and TGF-β1, blocking the TGF-β1-Smad signaling pathway, and regulating various signaling pathways to form a comprehensive anti-fibrotic network [2]

本文字数：829，阅读时长大约2分钟 作者 |第一财经 林志吟 封图 |AI生成 2025.09.01 东阳光药方面对第一财经记者表示，公司此次成立的肝病专线，设有上海、广州、北京等七大业务区， 总规模达百人级。 我国约有1000万丙肝感染者，但诊断率及抗病毒治疗率均较低，已成为严重的社会和公共卫生问题。东 阳光药东卫卓、东英贺的上市，可为国内丙肝患者提供新的治疗选择。不过，东阳光药仍面临其他丙肝 药物厂家竞争。 东卫卓、东英贺属于丙肝直接抗病毒药物（DAA），截至目前，中国共批准17种治疗慢性丙型肝炎的 DAA，其中八种药品已纳入国家医保药品目录。东阳光药能否从丙肝药物市场中突围，也在考验公司 的商业化能力。 根据东阳光药近期发布的半年报，公司在试图推动东卫卓、东英贺这两款药物进入新一轮国家医保目 录。 微信编辑| 夏木 第一财经持续追踪财经热点。若您掌握公司动态、行业趋势、金融事件等有价值的线索，欢迎提供。专 用邮箱：bianjibu@yicai.com 9月1日，第一财经记者从东阳光药（06887.HK）独家获悉，该公司于8月进行了销售架构调整，成立了 肝病专线团队，将加速丙肝等创新药商业化。 今年一季 ...

2025.09. 01 东阳光药有着"流感药物之王"称号，旗下的流感药物奥司他韦（商品名：可威）长期占据着国内主要 市场份额，凭借在儿童市场的优势地位，2025年上半年，整体销售额仍达到13.01亿元，但也受制于 竞争厂家激增等因素影响，销售额增长已出现疲软态势。 近年来，东阳光药努力在摆脱对奥司他韦销售的业绩依赖，后者在公司销售占比已从2022年的 81.2%下降至2024年的64.2%；今年上半年，东阳光药奥司他韦销售额占比约67%。 肝病业务正成为东阳光药在培育的第二增长曲线。截至目前，公司共有三款肝病药物获批上市。 本文字数：829，阅读时长大约2分钟 作者 | 第一 财经 林志吟 封图 | AI生成 9月1日，第一财经记者从东阳光药（06887.HK）独家获悉，该公司于8月进行了销售架构调整，成 立了肝病专线团队，将加速丙肝等创新药商业化。 今年一季度，东阳光药有两款丙肝创新药获批国内上市，分别是东卫卓（磷酸萘坦司韦）、东英贺 （艾考磷布韦），两药联合治疗初治或干扰素经治的基因1、2、3、6型成人慢性丙肝病毒（HCV） 感染，可合并或不合并代偿性肝硬化。 微信编辑 | 夏木 第 一 财 经 持 续 ...

Summary of Key Points Core Viewpoint - Dongyangguang Pharmaceutical (06887.HK) reported a significant decline in revenue and profit for the six months ending June 30, 2025, indicating potential challenges in its business operations [1]. Financial Performance - Revenue for the period was RMB 1,937.67 million, a decrease of 24.95% year-on-year [1]. - Gross profit amounted to RMB 1,467.61 million, reflecting a year-on-year decline of 28.12% [1]. - The total loss attributable to equity holders of the company was RMB 54.27 million, a decrease of RMB 192.90 million compared to a profit of RMB 138.63 million in the same period last year [1]. - Basic and diluted loss per share was RMB 0.11 [1].

Core Viewpoint - Dongyangguang Pharmaceutical (06887) reported a mid-year revenue of 1.938 billion RMB and a gross profit of 1.468 billion RMB, highlighting its diversified market strategy and focus on enhancing the competitiveness of its core products [1] Group 1: Financial Performance - The company achieved a revenue of 1.938 billion RMB and a gross profit of 1.468 billion RMB for the mid-year of 2025 [1] - The sales of Oseltamivir, a key product for flu treatment, reached 1.301 billion RMB, although it faced some impact due to a slowdown in flu cases compared to the same period last year [1] Group 2: Strategic Initiatives - The company is implementing a diversified market strategy, which includes ongoing academic promotion activities and optimizing channel construction to enhance the market competitiveness and commercial value of its core products [1] - Increased investments in advertising, marketing activities, and patient education are aimed at improving brand awareness of core products [1] - Strengthening strategic partnerships with internationally renowned companies to accelerate the development and commercialization of innovative drugs and biopharmaceuticals in international markets [1] Group 3: Research and Development - The company focuses on core therapeutic areas such as infections, chronic diseases, and oncology, adhering to an independent innovation research and development strategy [1] - Dongyangguang Pharmaceutical has over 150 approved drugs, with 3 innovative drugs already on the market and 100 drugs under research, including 49 first-class innovative drugs [1] - Among the first-class innovative drugs under research, there is 1 drug for which a New Drug Application (NDA) has been submitted to the regulatory authority, and 10 drugs are in Phase II or III clinical trials [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 的 中 期 業 績 公 告 財 務 摘 要 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月，本 集 團 錄 得： 中 期 股 息 • 董 事 會 議 決 不 派 付 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 的 中 期 股 息（截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月：無）。 – 1 – • 營 業 額 為 人 民 幣1,937.67百 萬 元，較 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 減 少24.95%。 • 毛 利 為 人 民 幣1,467.61百 萬 元，較 截 至 二 ...

Core Viewpoint - Dongyangguang Pharmaceutical (06887) announced the board's approval to convert 251 million domestic shares into H-shares, representing approximately 43.59% of the total issued share capital as of the announcement date [1] Group 1 - The company plans to apply for the conversion of domestic shares to H-shares, which requires approval from the China Securities Regulatory Commission and the Stock Exchange [1]

格隆汇8月29日丨东阳光药(06887.HK)公告，于2025年8月29日，公司董事会已审议及批准建议实施公司 若干股东持有的公司251,378,534股内资股转换为公司H股，占公司于本公告日期已发行股本总额约 43.59%。H股全流通拟申请流通的内资股数量尚需向中国证监会备案及联交所批准。 ...